Pregled bibliografske jedinice broj: 89494
Incidence of hepatitis C virus RNA in anti-HCV negative plasma pools in Croatia
Incidence of hepatitis C virus RNA in anti-HCV negative plasma pools in Croatia // Transfusion and Apheresis Science, 24 (2001), 3; 269-278 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 89494 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Incidence of hepatitis C virus RNA in anti-HCV negative plasma pools in Croatia
Autori
Forčić, Dubravko ; Zgorelec, Renata ; Branović, Karmen ; Košutić-Gulija, Tanja ; Šantak, Maja ; Mažuran, Renata
Izvornik
Transfusion and Apheresis Science (1473-0502) 24
(2001), 3;
269-278
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
hepatitis C; polymerase chain reaction; viral RNA; epidemiology; blood; human
Sažetak
The risks of transmitting viral infection by blood and products derived from plasma have long been known and still remain an area of concern. Blood banks and transfusion centres are faced with the imminent introduction of nucleic acid amplification testing (NAT) of plasma pools as used by the plasma industry. In this paper, we show a part of our results of a validation study of an in-house method for routine polymerase chain reaction (PCR) screening for hepatitis C virus (HCV) RNA in plasma pools and the results of testing 2718 anti-HCV negative plasma pools for the presence of HCV RNA. The European Committee for Proprietary Medical Products (CPMP) recommended that from I July 1999, only batches derived from plasma pools tested and found non-reactive for HCV RNA, using validated test methods of suitable sensitivity and specificity, should be batch released by authorities. The quality and efficiency of NAT detection of HCV RNA is among others influenced by the efficacy of RNA isolation, the primer selection and the use of control samples. Using modern molecular biology techniques (sensitive and specific in-house amplification methods for detection of HCV RNA and automated sequencing), we analysed samples of plasma pools from different Croatian transfusion centres. By detection of HCV RNA in an NIBSC working reagent (genotype 3) and a Pelispy HCV RNA run control (genotype 1) we determined a high reproducibility and sensitivity (below 100 International Units (IU)/ml) for our in-house method. By direct sequencing PCR cDNAs we proved the specificity of the test system and the possibility of determining the HCV genotype when the method was used for PCR screening of HCV RNA in single donations. Of 2718 anti-HCV negative plasma pools we have found that 2.1% were HCV RNA positive. Results of our investigation confirm the necessity of testing HCV RNA in plasma pools to further increase the safety of human plasma-derived drugs.
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti
POVEZANOST RADA
Projekti:
021001
Ustanove:
Imunološki zavod d.d.
Profili:
Maja Šantak
(autor)
Renata Mažuran
(autor)
Dubravko Forčić
(autor)
Tanja Košutić Gulija
(autor)
Karmen Branović-Čakanić
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE
Uključenost u ostale bibliografske baze podataka::
- SCIex